Up 12% on news that the FDA will review the resubmission.
After being up 80% on news that the FDA will accept a resubmission and review it.
A resubmission for approval for the third time.
None of this is unexpected or surprising. And the verdict is still just as uncertain as it always has been.
I would be wary buying at these prices, as it seems to be very hype driven. It's absolutely not driven by fundamentals at this point.
IMO, DYOR.
Fingers crossed third time is the charm
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-110
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
0.130(10.4%) |
Mkt cap ! $1.575B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $7.045M | 5.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 225211 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 18335 | 2 |
View Market Depth
| Last trade - 11.30am 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |